COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,100 Articles (22,658 medRxiv, 8,442 bioRxiv)

Most recent first Previous |  Page 1239: Articles 12381-12390  | Next

A randomized controlled trial of inhaled ciclesonide for outpatient treatment of symptomatic COVID-19 infections
Clemency, B. M., Varughese, R., Gonzalez-Rojas, Y., Morse, C. G., Phipatanakul, W., Koster, D. J., Blaiss, M. S.
10.1101/2021.09.07.21261811 — Posted: 2021-09-12
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Bergman, P., Blennow, O., Hansson, L., Mielke, S., Nowak, P., Chen, P., Soderdahl, G., Osterborg, A., Smith, C. I. E., Wullimann, D., Vesterbacka, J., Lindgren, G., Blixt, L., Friman, G., Borgstrom, E. W., Nordlander, A., Gomez, A. C., Akber, M., Valentini, D., Norlin, A.-C., Thalme, A., Bogdanovic, G., Muschiol, S., Nilsson, P., Hober, S., Lore, K., Sallberg Chen, M., Buggert, M., Ljunggren, H.-G., Ljungman, P., COVAXID collaborator group, , Aleman, S.
10.1101/2021.09.07.21263206 — Posted: 2021-09-12
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2
Walker, L. E., FitzGerald, R., Saunders, G., Lyon, R., Fisher, M., Martin, K., Eberhart, I., Woods, C., Ewings, S., Hale, C., Rajoli, R. K., Else, L., Dilly-Penchala, S., Amara, A., Lalloo, D. G., Jacobs, M., Pertinez, H., Hatchard, P., Waugh, R., Lawrence, M., Johnson, L., Fines, K., Reynolds, H., Rowland, T., Crook, R., Byrne, K., Mozgunov, P., Jaki, T., Khoo, S., Owen, A., Griffiths, G., Fletcher, T. E.
10.1101/2021.09.10.21263376 — Posted: 2021-09-11
The anticipated artificial increase in life expectancy from COVID-19
Kissler, S. M., Grad, Y.
10.1101/2021.09.09.21263351 — Posted: 2021-09-11
The contribution of hospital-acquired infections to the COVID-19 epidemic in England in the first half of 2020
Knight, G. M., Pham, T. M., Stimson, J., Funk, S., Jafari, Y., Pople, D., Evans, S., Yin, M., Brown, C., Bhattacharya, A., Hope, R., Semple, M. G., ISARIC4C Investigators, , CMMID COVID-19 working group, , Read, J. M., Cooper, B. S., Robotham, J. V.
10.1101/2021.09.02.21262480 — Posted: 2021-09-10
Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants
Wirnsberger, G., Monteil, V., Eaton, B., Postnikova, E., Murphy, M., Braunsfeld, B., Crozier, I., Kricek, F., Niederhoefer, J., Schwarzboeck, A., Breid, H., Sanchez Jimenez, A., Bugajska-Schretter, A., Dohnal, A., Ruf, C., Gugenberger, R., Hagelkrueys, A., Montserrat, N., Holbrook, M., Oostenbrink, C., Shoemaker, R. H., Mirazimi, A., Penninger, J. M.
10.1101/2021.09.10.459744 — Posted: 2021-09-10 Discussion: Onsite
Pharmacological perturbation of intracellular dynamics as a SARS-CoV-2 antiviral strategy
Bakhache, W., Partiot, E., Lucansky, V., Bare, Y., Bonaventure, B., Goujon, C., Bories, C., Deffieu, M. S., Gaudin, R.
10.1101/2021.09.10.459410 — Posted: 2021-09-10
Intranasal administration of a VLP-based vaccine against COVID-19 induces neutralizing antibodies against SARS-CoV-2 and Variants of Concerns
Rothen, D. A., Krenger, P. S., Nonic, A., Balke, I., Vogt, A.-C., Chang, X., Manenti, A., Vedovi, F., Resevica, G., Walton, S., Zeltins, A., Montomoli, E., Vogel, M., Bachmann, M. F., Mohsen, M. O.
10.1101/2021.09.10.459749 — Posted: 2021-09-10
Differential antibody dynamics to SARS-CoV-2 infection and vaccination
Chen, Y., Tong, P., Whiteman, N. B., Moghaddam, A. S., Zuiani, A., Habibi, S., Gautam, A., Xiao, T., Cai, Y., Chen, B., Wesemann, D. R.
10.1101/2021.09.09.459504 — Posted: 2021-09-10
Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity
Barsi, S., Papp, H., Valdeolivas Urbelz, A., Toth, D. J., Kuczmog, A., Madai, M., Hunyady, L., Varnai, P., Saez-Rodriguez, J., Jakab, F., Szalai, B.
10.1101/2021.09.10.459786 — Posted: 2021-09-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).